USANew treatments and approvals
US approval of concizumab expanded to hemophilia A and B without inhibitors
A decision by a medicines regulator (FDA, European Commission, etc.). The regulator has reviewed the clinical studies behind the drug. For accelerated or conditional approvals, the lasting benefit is still being confirmed.
The FDA approved concizumab, previously approved for patients with inhibitors, also for preventing bleeding in patients aged 12 years and older with hemophilia A and B without inhibitors. The drug is injected under the skin every day with a prefilled pen. In the phase 3 explorer8 study, the annual bleeding rate fell by 86% in hemophilia A and 79% in hemophilia B compared with no treatment.
What does it mean for patients and families?
There is a preventive treatment option that does not require a vein. This option has now opened up to a wider group of patients. Availability in Türkiye depends on TİTCK (Turkish Medicines and Medical Devices Agency) and SGK (Social Security Institution) processes.
Source
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Hemophilia (A and B)
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.